Approved for Rheumatoid arthritis (moderate to severe, in adults who had inadequate response to methotrexate), Psoriatic arthritis (active, in adults who had inadequate response to DMARDs), Atopic dermatitis (moderate to severe, in adults and pediatric patients 12+ years). Upadacitinib is a Janus kinase (JAK) inhibitor. JAK enzymes transmit signals from cytokines and growth factors involved in…
Loading full data from Know Your Drugs Institute…